home icon Return Home...

Sunridge International Introduces Its New Wholly Owned Subsidiary

(Wed, Jan 13)

Press Release Source: Sunridge International On Wednesday January 13, 2010, 9:15 am EST

 

FOUNTAIN HILLS, Ariz., Jan. 13 /PRNewswire-FirstCall/ -- Sunridge International's (OTC Bulletin Board: SNDZ) newly acquired wholly owned subsidiary Ophthalmic International (OI), is an innovative manufacturer of medical products.  OI has developed and patented a 2-minute, non-invasive, cost effective, alternative treatment for glaucoma and ocular hypertension, known as Pneumatic Trabeculoplasty (PNT).  OI holds worldwide patents on the PNT equipment, its disposable sterile suction ring, as well as the medical procedure itself.  OI having secured 2a CE marketing approval throughout Europe and Canada is currently marketing its product line through an exclusive distributor network.

 

Glaucoma is the second leading cause of blindness, effecting over 70 million people worldwide.  PNT has been proven (through studies completed over the last 10 yrs) to be a safe and effective treatment with no adverse side effects, unlike medications usually prescribed to treat glaucoma that come with a multitude of side effects.  For more information visit our website, www.oi-pnt.com.  

Contact: Jeff Smith
Phone: 602-363-6344
Email: cdik837@aol.com

 

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that such  forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.

 

Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.